N/A N=48 Gingival Bleeding and Von Willebrand Disease Typ 2 and 3
Gingival Bleeding · Von Willebrand Diseases
Primary: Bleeding on Probing (BOP) — 14.5; 12.3 percentage of sites
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=122 Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Chronic HCV Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 99.0; 100.0; 100.0; 83.3 percentage of participants
N/A N=56 Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment
Von Willebrand Diseases
Primary: Total Annualized Bleeding Rate (TABR) — 29.13 Bleeding events per year
Phase 3 N=41 A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Factor XIII Deficiency
Primary: The Incidence of Spontaneous Bleeding Events Requiring Treatment (Treatment is Defined as Administration of a FXIII-Containing Product to Treat the Bleeding Event) — 0…
Phase 3 N=61 An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Factor XIII Deficiency
Primary: Adverse Events — 42; 2; 2 participants
Phase 2 N=15 A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency
Factor XIII Deficiency
Primary: Peak FXIII Concentration at Steady State — 0.9 Units/mL
Phase 2 N=23 Rituximab to Treat Severe Hemophilia A
Hemophilia A
Primary: Proportion of Subjects With Major Response, i.e. Inhibitor Level Falls to Less Than 5 BU/mL Between Weeks 6 to 22 and Remains Below 5 BU/mL at 5-7 Days Following…
N/A N=72 Clinical Trial of Factor XIII (FXIII) Concentrate
Hemophilia · Factor XIII Deficiency
Primary: Response to Treatment of Bleeding Events Requiring Additional Factor XIII Infusions — 30; 1; 0; 3 Number of bleeds
Phase 3 N=25 Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery
Congenital Fibrinogen Deficiency
Primary: Overall Clinical Assessment of the Haemostatic Efficacy of Octafibrin in Treating the First Documented Bleeding Episode of Each Patient. — 19; 23; 5; 1 Participants
N/A N=265 Type 3 Von Willebrand International Registries Inhibitor Prospective Study
Type 3 Von Willebrand's Disease
Primary: Centralized Factor VIII (FVIII) Procoagulant Activity (FVIII:C) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis — 2.42 IU/dL
Phase 3 N=20 Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial
Von Willebrand Diseases · Postpartum Hemorrhage
Primary: Volume of Quantitative Blood Loss at Delivery — 727.0; 539.7 mL
N/A N=14 Low-Cost Platelet-Rich Plasma for Hemarthropathy
Hemarthrosis · Hemophilia
Primary: Global Satisfaction (Numeric Rating System) — 70 Scores on a scale
Phase 3 N=57 Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures
Blood Coagulation Disorders · Hemorrhage
Primary: Change in Hemoglobin Level — -0.6; -0.4 g/dL
N/A N=17 Bilateral Deficit Phenomenon in Patients With Haemophilic Arthropathy
Hemophilia
Primary: Assessment of Bilateral Index of Maximal Peak Force — -40.86 percentage
Phase 3 N=38 Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen
Hemophilia A · Hemophilia B
Primary: Percentage of Bleeding Episode With "Treatment Success" — 96.19; 79.30 percent of bleeding episodes
Phase 2 N=12 Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease
Blood Platelet Disorders
Primary: Response to Drug Based on Platelet Count at the End of Therapy — 91.6 percentage of participants
Phase 4 N=21 Prophylaxis Regimen for Hemophilia A Patients
Hemophilia A · Prophylaxis of Bleeding
Primary: Overall Number of Participants With Favorable Outcome on the Score-assigned Prophylaxis Regimen — 12 participants
Phase 3 N=134 A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A
Hemophilia A
Primary: Annualized Number of Total Bleeds in On-demand Treatment Arm (Weeks 0 -36) and in Each Prophylaxis Arm (Weeks 10 - 36, Excluding Rescue Bleeds) - Part A, Main Trial…
Phase 1 N=24 Thrombosomes® in Bleeding Thrombocytopenic Patients
Thrombocytopenia · Hematologic Diseases · Bone Marrow Aplasia
Primary: Number of Patients With Treatment-Emergent Adverse Events (TEAE) — 7; 6; 5 Participants
Phase 3 N=36 A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood
Treatment of Bleeding · Prophylaxis of Bleeding · Hemophilia A
Primary: Adverse Events of Special Interest (AESI) Hypersensitivity and Loss of Efficacy Associated With the First 4 Exposure Days (EDs) Leading to Discontinuation — 1 Participants
Phase 3 N=41 Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
Congenital Bleeding Disorder · Congenital FXIII Deficiency
Primary: Rate (Number Per Subject Year) of Bleeding Episodes Requiring Treatment With a FXIII Containing Product During the Treatment Period — 0.138 bleeding episodes per subject…
N/A N=1,439 Epidemiology of Severe Peroperative Bleeding During Scheduled Surgery
Surgery · Blood Loss
Primary: Unanticipated Bleeding — 0; 100; 0 percentage of participants
Phase 3 N=29 Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Acquired Hemophilia A
Primary: Percentage of Serious Bleeding Episodes Responsive to OBI-1 — 100 percentage of serious bleeding episodes — p=<0.001
N/A N=50 Diet and Hereditary Haemorrhagic Telangiectasia
Hereditary Haemorrhagic Telangiectasia (HHT)
Primary: Number of Participants That Achieving Personal Recommended Intake of Iron — 43 Participants
Phase 2 N=144 Pomalidomide for the Treatment of Bleeding in HHT
Telangiectasia, Hereditary Hemorrhagic
Primary: Change From Baseline Epistaxis Severity Score — -1; -1.1; -1.3; -1.2 units on a scale
Phase 4 N=72 Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy
Heart Failure
Primary: Safety Endpoint: % of Patients With Non-surgical Bleeding at 6 Months Post HeartMate II Implant — 12; 15 Participants
N/A N=22 Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy
Hemophilia · Hemophilic Arthropathy
Primary: Pain (Visual Analogue Scale) and Change From Baseline at 1, 2, 3 &6 Months — 5.0; 4.1; 2.5; 1.8 scores on a scale — p=<0.05
Phase 3 N=35 A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)
Von Willebrand Disease (VWD)
Primary: Spontaneous Annualized Bleeding Rate (sABR) — 1.430; 1.040; 0.000; 3.022 spontaneous bleeds per year
Phase 4 N=30 Prophylaxis Versus on Demand Treatment for Children With Hemophilia A
Hemophilia A
Primary: Difference of Annualized Number of All Bleeds Between On-demand and Prophylaxis Period — 56.00 Bleeds
Phase 2 N=7 IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia
Von Willebrand Disease
Primary: >50% Reduction in PBAC (Pictorial Blood Assessment Chart) at 6 Months — 71 percentage of participants